VRP on London Stock Exchange

Verona Pharma

Logo: veronapharma.com3

British pharmaceutical preparations company based in London.1

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Wave Life Sciences, PALVELLA THERAPEUTICS, INC. or Biofrontera Inc., or pick any stock.

  • TickerVRP on London Stock Exchange1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLondon1
  • Websitewww.veronapharma.com
  • Legal formpublic limited company1
  • Incorporated inUnited Kingdom4
  • Business address3 More London Riverside, London, X0 Se1 2Re4
  • Filer categoryLarge accelerated filer4

See how the biggest companies compare on our leaderboards

Verona Pharma image from its website
Image: veronapharma.com3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-365.7%Operating margin5
-410.2%Net margin5
-84.8%Return on equity5
0.59×Debt to equity5
-$122.8MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development81¢$44.6M
  • Income tax19¢$10.3M

Out of $42.3M in revenue.5 The company lost money this year.

Financial statements

Revenue675$42.3M in 2024
0$20.0M$40.0M$60.0M2020: $0$020202021: $40.0M$40.0M20212022: $458.0K$458.0K2022−99%2023: $0$020232024: $42.3M$42.3M2024
Gross profit78$0 in 2023
0$10.0M$20.0M$30.0M$40.0M2021: $40.0M$40.0M20212022: $112.0K$112.0K2022−100%2023: $0$02023
Operating income910675-$154.6M in 2024+504% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$25.6M-$25.6M20182019: -$52.4M-$52.4M2019+105%2020: -$74.3M-$74.3M2020+42%2021: -$73.3M-$73.3M2021−1%2022: -$75.8M-$75.8M2022+3%2023: -$67.6M-$67.6M2023−11%2024: -$154.6M-$154.6M2024+129%
Net income910675-$173.4M in 2024+771% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$19.9M-$19.9M20182019: -$40.6M-$40.6M2019+104%2020: -$65.1M-$65.1M2020+61%2021: -$55.6M-$55.6M2021−15%2022: -$68.7M-$68.7M2022+24%2023: -$54.4M-$54.4M2023−21%2024: -$173.4M-$173.4M2024+219%
Fiscal year2018201920202021202220232024
Revenue$06$40.0M7$458.0K5$05$42.3M5
Cost of revenue$07$346.0K8$08
Gross profit$40.0M7$112.0K8$08
Research and development$42.4M10$44.5M6$79.4M7$49.3M5$17.2M5$44.6M5
Operating income-25.6M GBP9-$52.4M10-$74.3M6-$73.3M7-$75.8M5-$67.6M5-$154.6M5
Interest$010$35.0K6$340.0K7$521.0K8$2.1M8
Income tax$72.0K10$146.0K6-$18.0K7$253.0K5$474.0K5$10.3M5
Net income-19.9M GBP9-$40.6M10-$65.1M6-$55.6M7-$68.7M5-$54.4M5-$173.4M5
Earnings per share-0 GBP/shares9-0 GBP/shares9-$0.127-$0.135-$0.095-$0.275
Earnings per share (diluted)-$0.127-$0.135-$0.095-$0.275

Compare Verona Pharma with another company

Leadership

Who has led Verona Pharma, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Zaccardelli2021–now

President

  1. David Zaccardelli2021–now

Chief financial officer

  1. Mark W. Hahn2021–now
2025
Board members and other officers (16)

Timeline

  1. Feb 1, 2021New chief executive David Zaccardelli becomes CEO15

Filings

367 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 38 major events, 212 insider forms, 40 large holders, 61 other. The latest 20:

  1. Nov 14, 2025EFFECT EDGAR
  2. Nov 14, 2025SCHEDULE 13G/A EDGAR
  3. Nov 14, 2025SCHEDULE 13G/A EDGAR
  4. Nov 14, 2025SCHEDULE 13G EDGAR
  5. Oct 17, 2025SCHEDULE 13G EDGAR
  6. Oct 17, 202515-12G EDGAR
  7. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  8. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  9. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  10. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  11. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  12. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  13. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  14. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  15. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  16. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  17. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  18. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  19. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR
  20. Oct 8, 20254 OWNERSHIP DOCUMENT EDGAR

The 367 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 40 such filings since October 2021, the latest 10:

  1. Nov 14, 2025SCHEDULE 13G/A
  2. Nov 14, 2025SCHEDULE 13G/A
  3. Nov 14, 2025SCHEDULE 13G
  4. Oct 17, 2025SCHEDULE 13G
  5. Aug 14, 2025SCHEDULE 13G/A
  6. Aug 14, 2025SCHEDULE 13G/A
  7. Aug 14, 2025SCHEDULE 13G/A
  8. May 15, 2025SCHEDULE 13G/A
  9. May 14, 2025SCHEDULE 13G
  10. Feb 14, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bank Of America Corp /de/12,168,127$295.8M0.0%+3,266,704
Morgan Stanley9,902,182$240.7M0.0%+500,402
Wells Fargo & Company/mn3,688,601$89.7M0.0%+196,954
LPL Financial LLC2,694,551$65.5M0.0%−199,519
UBS Group AG2,251,040$54.7M0.0%+11,246
Stephens Inc /ar/1,641,083$39.9M0.4%+162,286
Jpmorgan Chase & Co1,578,794$38.4M0.0%−80,749
Advisors Capital Management, LLC1,557,556$37.9M0.4%+74,357
Envestnet Asset Management Inc1,238,400$30.1M0.0%−196,440
HighTower Advisors, LLC1,208,761$29.4M0.0%+18,123
Insight Wealth Strategies, LLC930,732$22.7M2.2%New
Raymond James Financial Inc904,088$22.0M0.0%+74,414
Estate Counselors, LLC877,991$21.3M1.8%New
Royal Bank Of Canada818,546$19.9M0.0%+96,705
Mader & Shannon Wealth Management, Inc.723,418$17.6M8.2%+829
Ameriprise Financial Inc615,177$15.1M0.0%−37,289
Osaic Holdings, Inc.523,362$12.7M0.0%−11,277
Stifel Financial Corp504,921$12.3M0.0%+51,440
Benjamin Edwards Inc478,808$11.6M0.1%−33,470
Evolution Wealth Advisors, LLC470,496$11.4M1.3%+1,200
Spectrum Asset Management, Inc.445,782$10.8M15.6%+339,660
Mml Investors Services, LLC426,541$10.4M0.0%+46,174
Sanctuary Advisors, LLC412,328$10.0M0.0%−5,653
Cordoba Advisory Partners LLC399,681$9.7M2.1%+16,036
Matthew Goff Investment Advisor, LLC396,749$9.6M1.6%−8,092

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Feb 11, 2022Steve CohenDemocratic, HouseBuy$50,001 - $100,000Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteVerona Pharma logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31